$74.39
4.36% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US09073M1045
Symbol
TECH
Sector
Industry

Bio-Techne Corporation Stock price

$74.39
+5.71 8.31% 1M
-6.40 7.92% 6M
-2.77 3.59% YTD
+12.13 19.48% 1Y
-44.85 37.61% 3Y
+19.37 35.20% 5Y
+51.64 226.99% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+3.11 4.36%
ISIN
US09073M1045
Symbol
TECH
Sector
Industry

Key metrics

Market capitalization $11.82b
Enterprise Value $12.03b
P/E (TTM) P/E ratio 79.28
EV/FCF (TTM) EV/FCF 49.10
EV/Sales (TTM) EV/Sales 10.27
P/S ratio (TTM) P/S ratio 10.09
P/B ratio (TTM) P/B ratio 5.53
Dividend yield 0.43%
Last dividend (FY24) $0.32
Revenue growth (TTM) Revenue growth 2.41%
Revenue (TTM) Revenue $1.17b
EBIT (operating result TTM) EBIT $244.66m
Free Cash Flow (TTM) Free Cash Flow $245.03m
Cash position $187.54m
EPS (TTM) EPS $0.94
P/E forward 64.22
P/S forward 9.67
EV/Sales forward 9.84
Short interest 2.29%
Show more

Is Bio-Techne Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Bio-Techne Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Bio-Techne Corporation forecast:

13x Buy
76%
4x Hold
24%

Analyst Opinions

17 Analysts have issued a Bio-Techne Corporation forecast:

Buy
76%
Hold
24%

Financial data from Bio-Techne Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
1,172 1,172
2% 2%
100%
- Direct Costs 396 396
7% 7%
34%
776 776
0% 0%
66%
- Selling and Administrative Expenses 323 323
9% 9%
28%
- Research and Development Expense 97 97
4% 4%
8%
356 356
8% 8%
30%
- Depreciation and Amortization 111 111
2% 2%
10%
EBIT (Operating Income) EBIT 245 245
12% 12%
21%
Net Profit 151 151
39% 39%
13%

In millions USD.

Don't miss a Thing! We will send you all news about Bio-Techne Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Bio-Techne Corporation Stock News

Neutral
PRNewsWire
about 22 hours ago
WEST SACRAMENTO, Calif. , Nov. 25, 2024 /PRNewswire/ -- Gemini Bioproducts, LLC ("GeminiBio"), a leading supplier of cell culture reagents and process liquids, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Florida-based healthcare private equity firm, today announced the acquisition of selected fetal bovine serum (FBS) product rights and inventory from Bio-Techn...
Neutral
Business Wire
4 days ago
NEW YORK--(BUSINESS WIRE)--OverT Bio, an NYC-based cell therapy company, today announced that it has been awarded a $120,000 G-Rex Grant from ScaleReadyTM, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH), and CellReadyTM. This grant will support OverT Bio's ongoing development efforts that will lead to next generation cell therapies for solid tumors, based...
Neutral
PRNewsWire
6 days ago
MINNEAPOLIS , Nov. 20, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities today announced a partnership with Leader Life Sciences. Under the agreement, Leader Life Sciences becomes a distributor of Bio-Techne's portfolio across the Gulf Cooperation Counc...
More Bio-Techne Corporation News

Company Profile

Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Biotechnology, Protein Platforms, Diagnostics, and Corporate. The Biotechnology segment supplies specialized proteins, such as cytokines and growth factors, immunoassays, antibodies and related reagents, as well as in situ hybridization, media and other cell culture products and reagents to the biotechnology research community. The Protein Platforms segment develops, manufactures, and sells tools to simplify protein analysis. The Diagnostics segment includes blood chemistry and blood gas quality controls, hematology instrument controls, diagnostic immunoassays, and other bulk and custom reagents for the in vitro diagnostic market worldwide. The company was founded on 1976 and is headquartered in Minneapolis, MN.

Head office United States
CEO Kim Kelderman
Employees 3,100
Founded 1976
Website www.bio-techne.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today